ALZAMEND NEURO INC (ALZN) Fundamental Analysis & Valuation

NASDAQ:ALZN • US02262M6057

Current stock price

0.8575 USD
-0.04 (-4.99%)
At close:
0.85 USD
-0.01 (-0.87%)
After Hours:

This ALZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALZN Profitability Analysis

1.1 Basic Checks

  • ALZN had negative earnings in the past year.
  • In the past year ALZN has reported a negative cash flow from operations.
  • In the past 5 years ALZN always reported negative net income.
  • In the past 5 years ALZN always reported negative operating cash flow.
ALZN Yearly Net Income VS EBIT VS OCF VS FCFALZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • With a Return On Assets value of -188.83%, ALZN is not doing good in the industry: 86.46% of the companies in the same industry are doing better.
  • ALZN has a Return On Equity of -349.38%. This is in the lower half of the industry: ALZN underperforms 74.47% of its industry peers.
Industry RankSector Rank
ROA -188.83%
ROE -349.38%
ROIC N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALZN Yearly ROA, ROE, ROICALZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALZN Yearly Profit, Operating, Gross MarginsALZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALZN Health Analysis

2.1 Basic Checks

  • ALZN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALZN has more shares outstanding
  • There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALZN Yearly Shares OutstandingALZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
ALZN Yearly Total Debt VS Total AssetsALZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 5M 10M

2.2 Solvency

  • ALZN has an Altman-Z score of -26.41. This is a bad value and indicates that ALZN is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ALZN (-26.41) is worse than 87.23% of its industry peers.
  • There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.41
ROIC/WACCN/A
WACCN/A
ALZN Yearly LT Debt VS Equity VS FCFALZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 1.99 indicates that ALZN should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.99, ALZN is not doing good in the industry: 77.56% of the companies in the same industry are doing better.
  • ALZN has a Quick Ratio of 1.99. This is a normal value and indicates that ALZN is financially healthy and should not expect problems in meeting its short term obligations.
  • ALZN's Quick ratio of 1.99 is on the low side compared to the rest of the industry. ALZN is outperformed by 75.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
ALZN Yearly Current Assets VS Current LiabilitesALZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALZN Growth Analysis

3.1 Past

  • ALZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.44%, which is quite impressive.
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ALZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.94% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.29%
EPS Next 2Y33.94%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALZN Yearly Revenue VS EstimatesALZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M
ALZN Yearly EPS VS EstimatesALZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALZN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALZN. In the last year negative earnings were reported.
  • Also next year ALZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALZN Price Earnings VS Forward Price EarningsALZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALZN Per share dataALZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALZN's earnings are expected to grow with 21.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.94%
EPS Next 3Y21.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALZN Dividend Analysis

5.1 Amount

  • No dividends for ALZN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALZN Fundamentals: All Metrics, Ratios and Statistics

ALZAMEND NEURO INC

NASDAQ:ALZN (4/10/2026, 8:05:54 PM)

After market: 0.85 -0.01 (-0.87%)

0.8575

-0.04 (-4.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11
Earnings (Next)N/A
Inst Owners6.46%
Inst Owner Change0%
Ins Owners0.53%
Ins Owner Change-1.08%
Market Cap3.26M
Revenue(TTM)N/A
Net Income(TTM)-7.63M
Analysts80
Price Target28.56 (3230.61%)
Short Float %6.51%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.71%
Min EPS beat(2)70.46%
Max EPS beat(2)84.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.05%
EPS NY rev (1m)0%
EPS NY rev (3m)9.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-4.59
EYN/A
EPS(NY)-3.04
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.57
OCFYN/A
SpS0
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.83%
ROE -349.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -26.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)294.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.08%
EPS Next Y67.29%
EPS Next 2Y33.94%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-67.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.32%
OCF growth 3YN/A
OCF growth 5YN/A

ALZAMEND NEURO INC / ALZN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ALZAMEND NEURO INC (ALZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALZN.


Can you provide the valuation status for ALZAMEND NEURO INC?

ChartMill assigns a valuation rating of 1 / 10 to ALZAMEND NEURO INC (ALZN). This can be considered as Overvalued.


What is the profitability of ALZN stock?

ALZAMEND NEURO INC (ALZN) has a profitability rating of 0 / 10.